NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy

Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer affecting about 50,000 patients each year in the US.

Click here to read more.

Recent Posts

See All

Tucson, AZ, May 16th, 2022 - https://www.pr.com/press-release/861616 NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of prepara

Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases whe